Stryker price target raised to $345 from $320 at Jefferies

Jefferies analyst Matthew Taylor raised the firm’s price target on Stryker to $345 from $320 and keeps a Buy rating on the shares following the company’s "strong beat and raise" report. The firm views Stryker as "a solid compounder" in a rebounding market and a medsurg "super cycle," the analyst tells investors.